Methodological recommendations on vaccination of the population with Pfizer vaccine have been approved in the Republic of Kazakhstan

By the resolution of the Chief State Sanitary Doctor of the Republic of Kazakhstan dated October 20, 2021, the methodological recommendations "Vaccination of the population against coronavirus infection with the mRNA vaccine "Komirnati" (Pfizer, USA) in the Republic of Kazakhstan" were approved.
These guidelines determine the procedure for vaccination against coronavirus infection.
Komirnati is an mRNA-based vaccine against CVI (modified with nucleosides) for the prevention of coronavirus infection caused by SARS-CoV-2. "Komirnati" does not contain a virus for the development of immune protection, it cannot cause an infection of CVI.
One bottle contains 6 doses of 0.3 ml after dilution.
1 dose (0.3 ml) contains 30 micrograms of vaccine against CVI (BNT162b2) based on mRNA (encapsulated in lipid nanoparticles) and excipients.
Transparent multi-dose bottle with a capacity of 2 ml, capped with a stopper and compressed with an aluminum cap with a plastic cap of the "flip-off" type.
The following persons are subject to vaccination against CVI:
- teenagers aged 12 years and older;
- pregnant women - from 16 to 37 weeks of pregnancy;
- women during lactation - after the end of the postpartum period (after 42 days).
Before vaccination, the examination for the presence of CVI and antibodies to coronavirus is not carried out.
Those who have had CVI are subject to vaccination against CVI 6 months after recovery, taking into account the assessment of the condition before vaccination. Vaccination of those who have been ill with CVI is allowed 3 months after recovery.
One of the important elements in the vaccination of the population is the preservation of the immunogenicity of vaccines throughout its transportation and storage, since the final effectiveness of immunization depends on this factor.
Filling of the refrigeration equipment with the vaccine is carried out taking into account the shelf life of the drugs. At the same time, vaccines with a shorter shelf life are released or used in the first place.
The shelf life of unopened, frozen vials is 9 months from the date of production only at temperatures from minus 90 °C to minus 60 °C.
When the vaccine is switched from a temperature regime from minus 90 °C to minus 60 °C (freezing level) to a temperature regime from plus 2 °C to plus 8 °C (defrosting level), the shelf life of the vaccine is 31 days from the date and time of transition.
During the shelf life of 9 months, unopened vials can be stored and transported at temperatures from minus 25°C to minus 15°C for a single period of up to 2 weeks, and then placed back in storage conditions at temperatures from minus 90 °C to minus 60 °C.
The vaccine is stored in its original packaging to protect it from light.
It is ensured that there is an emergency plan in case of a power outage with instructions on the actions of all persons involved in the storage, transportation and use of the vaccine.

To read the full text of the document, follow the link:
https://www.gov.kz/memleket/entities/kkkbtu/press/news/details/272602?lang=ru